Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

Oncotarget
Alberto Carretero-GonzálezGuillermo de Velasco

Abstract

Anti-PD1/PD-L1 monoclonal antibodies (mAbs) increase overall survival compared to standard of care (SOC) in different tumors. However, a proportion of patients (pts) will have progressive disease (PD) as best response. We conducted a meta-analysis to study the rates of response comparing these antibodies with SOC. A search of published trials in MEDLINE and EMBASE analyzing anti-PD1/PD-L1mAbs monotherapy compared to SOC. Relative risk (RR) with 95% confidence interval (CI) of response rates between groups was estimated. Subgroup analyses for location of primary tumor, number of previous treatment lines, selected population by PD-L1 expression and type of radiological assessment were made. Twelve studies accounting for 6,700 pts were included (anti-PD1/PD-L1 mAbs: 3,451 pts; SOC: 3,249 pts [2,823 pts: chemotherapy, 426 pts: targeted therapy]). Adjusted response rates were (N, %): Complete Response (CR) (69/3153, 2.19%), Partial Response (PR) (596/3153, 18.90%), Stable Disease (SD) (632/2463, 25.66%) and PD (1027/2463, 41.70%); and CR (16/2955, 0.54%), PR (263/2955, 8.90%), SD (835/2269, 36.80%) and PD (834/2269, 36.76%) with anti-PD1/PD-L1 mAbs and SOC, respectively. Anti-PD1/PD-L1 mAbs improved CR rate (RR 3.48) and PR rate (RR...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1981·Cancer·A B MillerA Winkler
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antoni RibasJohn A Glaspy
Jun 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mizuki NishinoF Stephen Hodi
Jul 31, 2013·Immunity·Daniel S Chen, Ira Mellman
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 12, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Victoria L Chiou, Mauricio Burotto
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiJedd D Wolchok
Mar 12, 2016·Cell·A Karolina Palucka, Lisa M Coussens
Apr 24, 2016·Cancer Discovery·Rajarsi Mandal, Timothy A Chan
Aug 31, 2016·OncoTargets and Therapy·Xin WangJinming Yu
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 3, 2016·The New England Journal of Medicine·Vassiliki A Boussiotis
Nov 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane ChampiatCharles Ferté
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group

❮ Previous
Next ❯

Citations

May 14, 2019·Oncotarget·Dinoop Ravindran Menon, Mayumi Fujita
Nov 13, 2019·Archives of Pathology & Laboratory Medicine·Eric E WalkUNKNOWN College of American Pathologists Personalized Health Care Committee
Jul 25, 2019·The Cancer Journal·Marina Baretti, Nilofer Saba Azad
Sep 10, 2019·Molecular Systems Design & Engineering·Jonathan OzikPaul Macklin
Dec 2, 2020·International Journal of Molecular Sciences·Kevinn Eddy, Suzie Chen
Sep 6, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katherine D GrayIrene M Min
Mar 11, 2020·Acta Pharmacologica Sinica·Qian WuJi Cao
Nov 19, 2020·Journal for Immunotherapy of Cancer·Hannan GaoFan Wang
Dec 19, 2020·Cell Death and Differentiation·Tak W Mak
Apr 26, 2021·Pharmacology & Therapeutics·Mohammad Kaisarul Islam, Johnson Stanslas
Sep 8, 2020·Journal of the American Chemical Society·Moustafa T Gabr, Sanjiv S Gambhir
Oct 9, 2021·Journal for Immunotherapy of Cancer·Elisa BaldelliMariaelena Pierobon

❮ Previous
Next ❯

Software Mentioned

meta package

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.